Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

December 19, 2023

https://www.globenewswire.com/news-release/2023/12/19/2798525/0/en/Inhibikase-Therapeutics-Issues-Letter-to-Shareholders-and-Provides-Update-on-Development-Programs.html

BOSTON and ATLANTA, Dec. 19, 2023 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease (“PD”), Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today issued a Letter to Shareholders.

Read more at globenewswire.com

Related news for (IKT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.